How do CARs work? Early insights from recent clinical studies targeting CD19 Journal Article


Authors: Davila, M. L.; Brentjens, R.; Wang, X. Y.; Riviere, I.; Sadelain, M.
Article Title: How do CARs work? Early insights from recent clinical studies targeting CD19
Abstract: Second-generation chimeric antigen receptors (CARs) are powerful tools to redirect antigen-specific T cells independently of HLA-restriction. Recent clinical studies evaluating CD19-targeted T cells in patients with B-cell malignancies demonstrate the potency of CAR-engineered T cells. With results from 28 subjects enrolled by five centers conducting studies in patients with chronic lymphocytic leukemia (CLL) or lymphoma, some insights into the parameters that determine T-cell function and clinical outcome of CAR-based approaches are emerging. These parameters involve CAR design, T-cell production methods, conditioning chemotherapy as well as patient selection. Here, we discuss the potential relevance of these findings and in particular the interplay between the adoptive transfer of T cells and pre-transfer patient conditioning.
Keywords: immunotherapy; gene therapy; chimeric antigen receptor; in-vivo; acute lymphoblastic-leukemia; chronic lymphocytic-leukemia; antitumor-activity; bone-marrow; cd28; adoptive; human t-cells; adoptive t-cell therapy; cd19; chimeric antigen receptors; enhanced survival
Journal Title: OncoImmunology
Volume: 1
Issue: 9
ISSN: 2162-4011
Publisher: Landes Bioscience  
Date Published: 2012-12-01
Start Page: 1577
End Page: 1583
Language: English
DOI: 10.4161/onci.22524
ACCESSION: WOS:000316281700013
PROVIDER: wos
PMCID: PMC3525612
PUBMED: 23264903
PMCID: PMC3525612
PUBMED: 23264903
Notes: --- - Review - "Source: Wos"
Altmetric Score
MSK Authors
  1. Renier J Brentjens
    198 Brentjens
  2. Marco Luis Davila
    23 Davila
  3. Michel W J Sadelain
    462 Sadelain
  4. Isabelle C Riviere
    168 Riviere
  5. Xiuyan Wang
    69 Wang